【レポートの概要（一部）】
1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease
3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2016-2026
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2015
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints
4. The Alzheimer’s Disease Drugs Market, 2016-2026
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2015
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2016-2026
4.4 The Alzheimer’s Disease Drugs Market Forecast 2016-2026
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2016-2026
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2016-2026
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2016-2026
4.8 Alzheimer’s Disease Drugs Pipeline, 2015
4.8.1 New Guidelines: FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.8.2 Will Novel Drug Development Strategies Prove Successful?
4.8.3 Solanezumab (Eli Lilly)
4.8.3.1 Solanezumab Sales Forecast 2016-2026
4.8.4 Gantenerumab (Roche)
4.8.4.1 Gantenerumab Pipeline Forecast, 2015-2026
4.8.5 MK-8931 (Merck)
4.8.5.1 The MK-8931 Pipeline Forecast, 2015-2026
4.8.6 Lu AE58054 (Lundbeck)
4.8.7 TTP488 (TransTechPharma)
4.8.8 LMTX (TauRx)
4.8.9 EVP-6124 (Forum Pharmaceuticals)
4.8.10 Axona (Accera)
4.8.11 AD-4833 (Takeda Pharmaceuticals)
4.9 Deep Brain Stimulation (Functional Neuromodulation)
4.10 Recent Research on Alzheimer’s Disease
5. Leading Companies in the Alzheimer’s Disease Drugs Market, 2015
5.1 Pfizer, Inc
5.1.1 Sales and Recent Performance Analysis, 2015
5.1.2 Pfizer: Aricept
5.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
5.2 Eisai
5.2.1 Sales and Recent Performance Analysis, 2015
5.2.2 Eisai: Aricept
5.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
5.2.4 Collaboration with Biogen
5.2.5 Partnership with GE Healthcare for Diagnostic Development
5.3 Forest Laboratories (Acquired by Actavis)
5.3.1 Acquisition by Actavis
5.3.2 Forest: Namenda
5.3.3 Namenda’s Sales and Recent Performance Analysis, 2014
5.4 Lundbeck A/S
5.4.1 Sales and Recent Performance Analysis, 2014
5.4.2 Lundbeck: R&D Capabilities
5.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
5.4.4 Lundbeck: Ebixa
5.5 Daiichi Sankyo
5.5.1 Financial Sales and Recent Performance, 2015
5.5.2 Daiichi Sankyo: Memary
5.6 Novartis AG
5.6.1 Sales and Recent Performance Analysis
5.6.2 Novartis: Exelon
5.6.3 eHealth Programme Delivering Innovation
5.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
5.7 TauRx
5.7.1 Partnership with Bayer Schering Pharma AG
5.8 vTv Therapeutics
5.8.1 TTP Translational Technology
5.8.2 vTv Therapeutics: Alzheimer’s Disease Pipeline Portfolio
6. The Alzheimer’s Disease Diagnostics Market, 2015-2026
6.1 There is Still a Strong Market Need for Effective Diagnosis
6.2 The Alzheimer’s Disease Diagnostics Market, 2015
6.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2015-2026
6.4 The Alzheimer’s Diagnostics Market, 2015-2026
6.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
6.6 Biomarkers for Alzheimer’s Disease
6.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
6.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
6.7.1 Structural Imaging
6.7.2 Functional Imaging
6.7.3 Molecular Imaging Technologies
6.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
6.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
6.7.3.3 Flutemetamol (GE Healthcare)
6.7.3.4 Florbetaben (Piramal Imaging)
6.8 Other Alzheimer’s Diagnostics in Development
6.8.1 CSF Proteins
6.8.2 Blood Based Biomarkers for Alzheimer’s Disease
6.8.3 Genetic Risk Profiling
6.8.4 Eye Tests
6.8.5 Nanoparticles
6.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2015
6.9.1 Eli Lilly
6.9.1.1 Recent Performance and Sales Analysis, 2015
6.9.1.2 Alzheimer’s Disease Research Effort
6.9.1.3 Solanezumab
6.9.1.4 Amyvid (Florbetapir F18)
6.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
6.9.1.6 LY-2886721: Terminated Drug
6.9.1.7 LY3002813: Phase I
6.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
6.9.2 Amarantus BioScience Holdings, Inc.
6.9.2.1 Recent Performance and Sales Analysis, 2014
6.9.2.2 LymPro
6.9.2.3 Intellectual Property Acquisitions
6.9.3 Piramal Enterprises
6.9.3.1 Piramal Imaging SA
6.9.3.2 U.S. and EMA Approval of Florbetaben
6.9.3.3 Manufacturing and Distribution Agreements
6.9.4 GE Healthcare
6.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
6.9.4.2 Regulatory Approval of Flutemetamol
6.9.4.3 Licensing Agreements for Flutemetamol
6.9.5 Navidea
6.9.5.1 NAV4694 (Fluorine-18)
6.9.5.2 Collaboration Agreements
6.9.5.3 NAV4694 Clinical Development
6.9.6 DiaGenic
7. The Leading National Markets, 2015-2026
7.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2015
7.1.1 The US, Japan and Europe Represent More than 80% of the Total Market
7.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2015-2026
7.3 Changing Market Shares of Leading National Markets 2015-2026
7.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2015-2026
7.4.1 One in Nine Over the Age of 65 has AD in the US
7.4.2 The US Will Remain the Largest Market Over the Forecast Period
7.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2015-2026
7.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
8. Qualitative Analysis of the Alzheimer’s Disease: Therapeutics and Diagnostics Market, 2016-2026
8.1 SWOT Analysis
8.2 Strengths
8.2.1 Alzheimer’s Disease is a High Profile Disease
8.2.2 Expanding Patient Population
8.2.3 Strong R&D Pipeline in Both Sectors of the Market
8.3 Weaknesses
8.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
8.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
8.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
8.4. Opportunities
8.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
8.4.2 Neurodegenerative Diseases Have Strong R&D
8.4.3 Emerging Markets Will Help Drive the Market
8.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
8.5 Threats
8.5.1 Patent Expiries Will Lead to Further Generic Competition
8.5.2 New AD Therapies Face Political, Commercial and Social Pressures
8.6 Porter’s Five Force Analysis
8.6.1 Rivalry Among Competitors
8.6.2 Threats of New Entrants
8.6.3 Powers of Suppliers
8.6.4 Bargaining Power of Buyers
8.6.5 Threat of Substitutes
9. Research Interviews from Our Survey
9.1 Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
9.1.1 Alzheimer’s Treatment in Late Stage Development
9.1.2 Alzheimer’s Severe Under diagnosis
9.1.3 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
9.1.4 Alzheimer’s Treatment: The Greatest Challenge
9.2 Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
9.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
9.2.2 Alzheimer’s Disease Diagnosis Biomarkers
9.2.3 Quanterix: Future Developments
9.3 The Alzheimer’s Association Northern California and Northern Nevada
9.3.1 Alzheimer’s Treatment in Late Stage Development
9.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
9.3.3 A Push to Improve the Success of Alzheimer’s Research
10. Conclusion
10.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
10.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
10.3 Demographics Will Help Drive the Market Over the Forecast Period
10.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2015 to 2026
10.5 Research for Alzheimer’s Happening all Over the World
【レポート販売概要】
■ タイトル：アルツハイマー病治療・診断の世界市場予測2016-2026■ 英文：Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026
■ 発行日：2016年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN60625
■ 調査対象地域：グローバル
- デルタロボットの世界市場2019-2023About this market Advanced software and control systems to improve performance to drive market growth. In the case of industrial robots, the control system is programmed to ensure that the devices' movements and performance to suit the end-user’s needs. End-users or system integrators write the robot programs. Vendors ensure that the necessary development in robots includes features that make prog …
- ハロゲン市場：韓国This report is a comprehensive research of halogens market in South Korea. The report starts with giving brief country profile for South Korea, including general information and main economic indicators. Further, the report provides in-depth analyses halogens market in the country. It identifies key market players, including major producers, wholesalers and distributing companies. The third chapte …
- ビデオ監視の世界市場：システム種類別（アナログ監視、IP監視、ハイブリッド監視）、コンポーネント別（ハードウェア、ソフトウェア、サービス）、用途別（商業、軍事、防衛、インフラ、住宅、その他）Video surveillance systems can be used for almost any environment. Owing to increase in adoption of advanced surveillance by the government sector, manufacturers have realized the need for optimum IP surveillance systems. There are many advantages that an IP camera CCTV system offers over an analog format. There has been an increase in demand for security applications such as video surveillance to …
- 腫瘍アブレーションの世界市場予測（～2021年）：ラジオ波アブレーション、マイクロ波アブレーション、冷凍アブレーション、IREアブレーション、超音波アブレーション、レーザアブレーションThe global tumor ablation market is expected to reach a value of USD 580.1 Million by 2021, at a CAGR of 12.5% during 2016-2021. A number of factors such as technological advancements in the field of tumor ablation focused on enhancing effectiveness and safety of the treatment, rising demand of minimal invasive tumor ablation techniques, increasing prevalence of cancer across the globe, and growin …
- 双極性障害市場：アメリカの治療薬市場Bipolar Disorder - US Drug Forecast and Market Analysis to 2024 Summary Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely gener …
- Switchgear Market for Power Industry, 2013 – Global Market Size, Equipment Market Share, Key Country Analysis to 2020Switchgear Market for Power Industry, 2013 Update - Global Market Size, Equipment Market Share, Key Country Analysis to 2020 Summary GlobalData’s "Switchgear Market for Power Industry, 2013 Update - Global Market Size, Equipment Market Share, Key Country Analysis to 2020" gives detailed information on the current switchgear market, focusing on key countries, as well as covering the global scenario …
- シリコーンフィルムの世界市場予測（～2023年）“The silicone film market is projected to grow at a CAGR of 6.5%, in terms of value, from 2018 to 2023.” The market size of silicone film is estimated to be USD 794 million in 2018 and is projected to reach USD 1,087 million by 2023, at a CAGR of 6.5% from 2018 to 2023. The growth of the market is attributed to the high growth of end-use industries consuming silicone film. Another factor driving t …
- 世界の軍事弾薬市場動向2013-2023：トレンド、開発動向及び課題Technological Developments in the global Military Ammunition include: ■ Precision Extended Range Munition to provide enhanced precision ■ Smart ammunition to result in increased lethality ■ Lead free small caliber ammunition in a step to reduce environmental contamination
- 副鼻腔炎(Sinusitis)：治療薬開発パイプライン動向（2015年上半期版）Sinusitis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Sinusitis - Pipeline Review, H1 2015’, provides an overview of the Sinusitis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sinusitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of admin …
- 地域別WiMAXサービスプロバイダー（WiMAX Service Providers by Country 2012）WiMAX service providers have a rich environment to create real business, not only providing services to traditional customers, but also to developing a solid ecosystem with other technology developers which are seeking for enhancing their WiMAX-based developed products. This developed ecosystem facilitates certain advantages for all ecosystem partners and such advantages are reflected to customers …
- BTAの世界市場2015BTA (CAS 95-14-7) Market Research Report 2015 aims at providing comprehensive data on BTA market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes BTA description, covers its application areas, manufacturing methods, patterns. It captures BTA market trends, pays close attention to BTA manufacturers and names suppliers. Besides, the report provides BTA pr …
- 食品・飲料用金属缶の世界市場：アルミ缶/スチール缶The global food & beverage metal cans market is marked with intense competition due to the presence of large number of big and small firms in the metal can manufacturing industry. This segment includes the growth strategies adopted by the market players between 2011 and 2014 to expand their market share. Expansions & investments, acquisitions, new product & technology launches, agreements, collabo …
- 1,3,4,6-テトラキスの世界市場1,3,4,6-Tetrakis(methoxymethyl)glycoluril (CAS 17464-88-9) Market Research Report 2014 presents comprehensive data on 1,3,4,6-tetrakis(methoxymethyl)glycoluril markets globally and regionally (Europe, Asia, North America etc.) The report includes 1,3,4,6-tetrakis(methoxymethyl)glycoluril description, covers its application areas and related patterns. It overviews 1,3,4,6-tetrakis(methoxymethyl)gly …
- Complera (HIV)：市場予測と分析（～2022）Complera (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Complera (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a d …
- United American Petroleum Corporation：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013United American Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary United American Petroleum Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. T …
